Nucleic Acid miRNA Detection for Accurate Stomach Cancer Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting stomach cancer, such as imaging tests and existing tumor markers, are inadequate for early detection, leading to high mortality rates and unnecessary burdens on patients due to false positives or negatives, and existing miRNA-based methods lack practicality and specificity.
Innovation Solution
The use of nucleic acids capable of specifically binding to miRNAs, such as hsa-miR-6088, for detecting stomach cancer in blood samples with limited invasiveness, providing a more accurate and convenient screening method.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If imaging tests (gastric X-ray, CT, PET, MRI) are used for stomach cancer screening, then detection capability is improved, but patient burden and healthcare costs increase
Solution Approach 1:
The patent replaces mechanical imaging tests (gastric X-ray, CT, PET, MRI) with a biochemical detection system based on miRNA expression analysis. The nucleic acid probe system detects cancer-specific miRNA markers in gastric fluid, substituting physical imaging with molecular biology-based detection that requires minimal patient preparation and exposure to radiation or complex procedures.
2Reliability
If existing tumor markers (CEA, CA19-9) are used for stomach cancer detection, then detection capability is improved, but false positives and negatives increase
Solution Approach 1:
The patent applies local quality by selecting specific miRNA markers (miR-21, miR-221, miR-222) that are locally expressed in stomach cancer tissues rather than using general tumor markers. The nucleic acid probes are designed to specifically bind to these cancer-associated miRNA sequences, providing localized molecular detection that distinguishes stomach cancer from other conditions, thereby reducing false positives and negatives.
Solution Approach 2:
The patent uses a composite approach by combining multiple miRNA markers (miR-21, miR-221, miR-222) into a panel for detection. This composite marker system provides more comprehensive and accurate detection compared to single markers, as the combination allows for cross-validation and reduces the impact of individual marker variability or non-specific expression.
3Measurement precision
If miRNA-based detection methods are developed, then detection accuracy is improved, but practicality and specificity decrease
Solution Approach 1:
The patent extracts only the essential miRNA detection function from complex research-stage miRNA-based methods. The nucleic acid probes are designed to specifically hybridize with target miRNA sequences, and the detection system focuses on quantifying miRNA expression levels in gastric fluid without requiring complex tissue analysis or multiple procedural steps. This extraction of the core detection mechanism improves practicality while maintaining accuracy.
4Measurement precision
If invasive procedures are used for tissue sampling, then detection accuracy is improved, but patient burden increases
Solution Approach 1:
The patent introduces gastric fluid as an intermediary medium between the patient and the detection system. Instead of directly analyzing gastric tissue through invasive biopsies, the method detects miRNA markers present in gastric fluid that can be obtained through less invasive means such as gastric lavage or aspiration during routine endoscopy. This intermediary approach maintains detection accuracy while significantly reducing patient burden and procedural invasiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for early and accurate detection of stomach cancer, reducing false positives and negatives, and minimizing invasive procedures, thereby improving patient outcomes and reducing healthcare costs.
Implementation Method 1
a nucleic acid(s) capable of specifically binding to a particular miRNA(s)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention relates to a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, comprising measuring the miRNA(s) in vitro.